Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
General news
Fauci 'cautiously optimistic' at least one Phase 3 vaccine trial starts in July » 12:36
06/05/20
06/05
12:36
06/05/20
12:36
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$319.72 /

+8.42 (+2.70%)

, MRNA

Moderna

$57.29 /

-3.31 (-5.46%)

, JNJ

Johnson & Johnson

$148.84 /

+2.18 (+1.49%)

, MRK

Merck

$82.61 /

+1.06 (+1.30%)

, PFE

Pfizer

$36.11 /

+0.105 (+0.29%)

, NVAX

Novavax

$46.00 /

+1.32 (+2.95%)

, INO

Inovio

$11.43 /

-0.44 (-3.71%)

, AZN

AstraZeneca

$54.12 /

+0.25 (+0.46%)

Fauci said he is…

Fauci said he is "cautiously optimistic" that "at least one" Phase 3 trial testing a COVID_19 vaccine candidate can start in early July and that "a few others" should be able to start by early fall. If things break correctly, "we can have an answer" by the end of this calendar year or early in 2021 if there is a safe and effective vaccine that has been found, added Fauci. Companies working on potential COVID-19 vaccines include Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ), Merck (MRK), Pfizer (PFE), Novavax (NVAX) and Inovio (INO). Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, is being interviewed on CNBC.

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$319.72 /

+8.42 (+2.70%)

SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.11 /

+0.105 (+0.29%)

NVAX Novavax
$46.00 /

+1.32 (+2.95%)

MRNA Moderna
$57.29 /

-3.31 (-5.46%)

MRK Merck
$82.61 /

+1.06 (+1.30%)

JNJ Johnson & Johnson
$148.84 /

+2.18 (+1.49%)

INO Inovio
$11.43 /

-0.44 (-3.71%)

AZN AstraZeneca
$54.12 /

+0.25 (+0.46%)

SPX S&P 500
$0.00 /

+ (+0.00%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPY SPDR S&P 500 ETF Trust
$319.72 /

+8.42 (+2.70%)

MRNA Moderna
$57.29 /

-3.31 (-5.46%)

06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
JNJ Johnson & Johnson
$148.84 /

+2.18 (+1.49%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
MRK Merck
$82.61 /

+1.06 (+1.30%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
06/03/20 Alliance Global Partners
OpGen, NYS DOH collaboration extension 'highly positive,' says Alliance Global
06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
PFE Pfizer
$36.11 /

+0.105 (+0.29%)

06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
06/01/20 Barclays
Pfizer price target lowered to $35 from $37 at Barclays
05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
NVAX Novavax
$46.00 /

+1.32 (+2.95%)

06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
INO Inovio
$11.43 /

-0.44 (-3.71%)

06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/01/20 Piper Sandler
Context 'may be necessary' for Inovio's INO-5401 GBM update, says Piper Sandler
05/21/20 Benchmark
Inovio initiated with a Buy at Benchmark
05/20/20 Roth Capital
Most of Inovio COVID-19 vaccine data 'over two months old,' says Roth Capital
AZN AstraZeneca
$54.12 /

+0.25 (+0.46%)

06/04/20 UBS
AstraZeneca price target raised to 7,300 GBp from 6,000 GBp at UBS
06/01/20 Piper Sandler
Aveo's tivozanib could launch in U.S. next year, says Piper Sandler
05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.11 /

+0.105 (+0.29%)

NVAX Novavax
$46.00 /

+1.32 (+2.95%)

MRNA Moderna
$57.29 /

-3.31 (-5.46%)

MRK Merck
$82.61 /

+1.06 (+1.30%)

JNJ Johnson & Johnson
$148.84 /

+2.18 (+1.49%)

INO Inovio
$11.43 /

-0.44 (-3.71%)

AZN AstraZeneca
$54.12 /

+0.25 (+0.46%)

SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.11 /

+0.105 (+0.29%)

NVAX Novavax
$46.00 /

+1.32 (+2.95%)

MRNA Moderna
$57.29 /

-3.31 (-5.46%)

MRK Merck
$82.61 /

+1.06 (+1.30%)

JNJ Johnson & Johnson
$148.84 /

+2.18 (+1.49%)

INO Inovio
$11.43 /

-0.44 (-3.71%)

AZN AstraZeneca
$54.12 /

+0.25 (+0.46%)

SPX S&P 500
$0.00 /

+ (+0.00%)

NVAX Novavax
$46.00 /

+1.32 (+2.95%)

MRNA Moderna
$57.29 /

-3.31 (-5.46%)

MRK Merck
$82.61 /

+1.06 (+1.30%)

JNJ Johnson & Johnson
$148.84 /

+2.18 (+1.49%)

INO Inovio
$11.43 /

-0.44 (-3.71%)

SPY SPDR S&P 500 ETF Trust
$319.72 /

+8.42 (+2.70%)

SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.11 /

+0.105 (+0.29%)

NVAX Novavax
$46.00 /

+1.32 (+2.95%)

MRNA Moderna
$57.29 /

-3.31 (-5.46%)

MRK Merck
$82.61 /

+1.06 (+1.30%)

JNJ Johnson & Johnson
$148.84 /

+2.18 (+1.49%)

INO Inovio
$11.43 /

-0.44 (-3.71%)

AZN AstraZeneca
$54.12 /

+0.25 (+0.46%)

SPY SPDR S&P 500 ETF Trust
$319.72 /

+8.42 (+2.70%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Upgrade
Fly Intel: Top five analyst upgrades » 10:06
06/05/20
06/05
10:06
06/05/20
10:06
NVAX

Novavax

$49.70 /

+5.02 (+11.24%)

, NAV

Navistar

$29.22 /

+1.3 (+4.66%)

, SYY

Sysco

$63.09 /

+4.51 (+7.70%)

, HXL

Hexcel

$48.77 /

+4.055 (+9.07%)

, WBK

Westpac

$13.51 /

+0.7 (+5.46%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Novavax (NVAX) upgraded to Neutral from Underweight at JPMorgan with analyst Eric Joseph saying the stock's 995% rally year-to-date reflects the potential promise for the company's COVID-19 vaccine program, NVX-CoV2373, having recently initiated phase 1 testing. 2. Navistar (NAV) was upgraded to Outperform from Neutral at Baird and to Buy from Hold at Loop Capital. 3. Sysco (SYY) upgraded to Overweight from Equal Weight at Wells Fargo with analyst Edward Kelly saying Kelly's confidence in the company's ability to navigate the COVID-19 disruption and emerge even stronger is growing. 4. Hexcel (HXL) upgraded to Outperform from Market Perform at BMO Capital with analyst John McNulty saying while the company's near-term earnings will be "abysmal" with significant production cuts in aerospace compounded by inventory destocking that can't be offset quickly enough with cost cutting, there are improving signs for the intermediate to long term with the 737 MAX ramp-up having started. 5. Westpac (WBK) upgraded to Buy from Neutral at UBS with analyst Jonathan Mott saying he Australian banks have de-rated but the outlooks "may not be as bleak." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WBK Westpac
$13.51 /

+0.7 (+5.46%)

SYY Sysco
$63.09 /

+4.51 (+7.70%)

NVAX Novavax
$49.70 /

+5.02 (+11.24%)

NAV Navistar
$29.22 /

+1.3 (+4.66%)

HXL Hexcel
$48.77 /

+4.055 (+9.07%)

NVAX Novavax
$49.70 /

+5.02 (+11.24%)

06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
NAV Navistar
$29.22 /

+1.3 (+4.66%)

06/05/20 Loop Capital
Navistar upgraded to Buy from Hold at Loop Capital
06/05/20 Baird
Navistar upgraded to Outperform from Neutral at Baird
06/05/20 Loop Capital
Navistar upgraded to Buy from Hold at Loop Capital
06/02/20 Longbow
Navistar downgraded to Neutral from Buy at Longbow
SYY Sysco
$63.09 /

+4.51 (+7.70%)

06/05/20 Wells Fargo
Sysco upgraded to Overweight from Equal Weight at Wells Fargo
06/05/20 Wells Fargo
Sysco upgraded to Overweight from Equal Weight at Wells Fargo
06/01/20 Piper Sandler
Sysco upgraded to Overweight from Neutral at Piper Sandler
04/23/20
Fly Intel: Top five analyst downgrades
HXL Hexcel
$48.77 /

+4.055 (+9.07%)

06/05/20 BMO Capital
Hexcel upgraded to Outperform from Market Perform at BMO Capital
06/01/20 Barclays
Barclays upgrades Woodward to Overweight on improved cash flow view
05/28/20 BMO Capital
Hexcel price target raised to $45 from $37 at BMO Capital
05/22/20 Alembic Global
Hexcel initiated with a Neutral at Alembic Global
WBK Westpac
$13.51 /

+0.7 (+5.46%)

06/04/20 UBS
Westpac upgraded to Buy from Neutral at UBS
06/01/20 Jefferies
Westpac downgraded to Underperform from Hold at Jefferies
04/27/20 JPMorgan
Westpac downgraded to Neutral from Overweight at JPMorgan
03/24/20 JPMorgan
Westpac upgraded to Overweight from Neutral at JPMorgan
SYY Sysco
$63.09 /

+4.51 (+7.70%)

NVAX Novavax
$49.70 /

+5.02 (+11.24%)

NAV Navistar
$29.22 /

+1.3 (+4.66%)

HXL Hexcel
$48.77 /

+4.055 (+9.07%)

SYY Sysco
$63.09 /

+4.51 (+7.70%)

NVAX Novavax
$49.70 /

+5.02 (+11.24%)

NAV Navistar
$29.22 /

+1.3 (+4.66%)

SYY Sysco
$63.09 /

+4.51 (+7.70%)

NVAX Novavax
$49.70 /

+5.02 (+11.24%)

NAV Navistar
$29.22 /

+1.3 (+4.66%)

HXL Hexcel
$48.77 /

+4.055 (+9.07%)

SYY Sysco
$63.09 /

+4.51 (+7.70%)

NVAX Novavax
$49.70 /

+5.02 (+11.24%)

Upgrade
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals' » 09:37
06/05/20
06/05
09:37
06/05/20
09:37
NVAX

Novavax

$44.68 /

+0.42 (+0.95%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph upgraded Novavax to Neutral from Underweight with an unchanged price target of $46. The stock's 995% rally year-to-date reflects the potential promise for the company's COVID-19 vaccine program, NVX-CoV2373, having recently initiated phase 1 testing, Joseph tells investors in a research note. However, much remains unknown about the nature of the virus and its pathology and ultimate size of the market opportunity longer-term, adds the analyst. As such, Joseph sees "shaky fundamentals" behind COVID-19 vaccine-driven valuations that would keep him from "chasing upside momentum from current levels." The outlook for Novavax shares is one of "further volatility in advance of clinical challenge data," adds the analyst.

ShowHide Related Items >><<
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/03/20 B. Riley FBR
Novavax selloff on 'Warp Speed' report unwarranted, says B. Riley FBR
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

Recommendations
Novavax price target raised to $74 from $61 at B. Riley FBR » 08:16
06/05/20
06/05
08:16
06/05/20
08:16
NVAX

Novavax

$44.68 /

+0.42 (+0.95%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani raised the firm's price target on Novavax to $74 from $61 and reiterates a Buy rating on the shares. The stock closed Thursday up 41c to $44.66. The company announced last night that the U.S. Department of Defense has granted it $60M to support the production of NVX-CoV2373 in the U.S., Mamtani tells investors in a research note titled "U.S. DoD Contract Locked In; Is Operation Warp Speed Next?" This development is in "sharp contrast" to the New York Times report this week that excluded Novavax from the list of five finalists chosen by the Trump administration via "Operation Warp Speed," says Mamtani. In fact, the Department of Defense contract strengthens the analyst's conviction in a "sizeable funding" to be secured from the Biomedical Advanced Research and Development Authority, which he notes has ~$4B left over from the original $6.5B allocation under the CARES Act for COVID-19 vaccine development and manufacturing. Mamtani recommends using the recent weakness in Novavax shares as a buying opportunity.

ShowHide Related Items >><<
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/03/20 B. Riley FBR
Novavax selloff on 'Warp Speed' report unwarranted, says B. Riley FBR
05/26/20 B. Riley FBR
Novavax has become a leading COVID vaccine candidate, says B. Riley FBR
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

Initiation
Rosenblatt starts 'misunderstood' Smart Global at Buy » 07:24
06/05/20
06/05
07:24
06/05/20
07:24
SGH

Smart Global

$28.20 /

+0.52 (+1.88%)

As previously reported,…

As previously reported, Rosenblatt analyst Kevin Cassidy initiated coverage of Smart Global with a Buy rating and $45 price target. Smart Global is "misunderstood by the market" as memory sub-systems have an increasing importance to overall system performance and are becoming increasing more complex to design, Cassidy argues. In addition, recent acquisitions have opened up revenue exposure to high growth markets such as high performance computing for artificial intelligence and the industrial Internet of Things, according to Cassidy.

ShowHide Related Items >><<
SGH Smart Global
$28.20 /

+0.52 (+1.88%)

SGH Smart Global
$28.20 /

+0.52 (+1.88%)

06/05/20 Rosenblatt
Smart Global initiated with a Buy at Rosenblatt
04/17/20 Barclays
Smart Global downgraded to Equal Weight on Brazil exposure at Barclays
04/17/20 Barclays
Smart Global downgraded to Equal Weight from Overweight at Barclays
04/08/20 Roth Capital
Smart Global price target lowered to $25 from $30 at Roth Capital
SGH Smart Global
$28.20 /

+0.52 (+1.88%)

SGH Smart Global
$28.20 /

+0.52 (+1.88%)

SGH Smart Global
$28.20 /

+0.52 (+1.88%)

Initiation
Smart Global initiated with a Buy at Rosenblatt » 05:14
06/05/20
06/05
05:14
06/05/20
05:14
SGH

Smart Global

$28.20 /

+0.52 (+1.88%)

Rosenblatt initiated…

Rosenblatt initiated coverage of Smart Global Holdings with a Buy rating and $45 price target.

ShowHide Related Items >><<
SGH Smart Global
$28.20 /

+0.52 (+1.88%)

SGH Smart Global
$28.20 /

+0.52 (+1.88%)

04/17/20 Barclays
Smart Global downgraded to Equal Weight on Brazil exposure at Barclays
04/17/20 Barclays
Smart Global downgraded to Equal Weight from Overweight at Barclays
04/08/20 Roth Capital
Smart Global price target lowered to $25 from $30 at Roth Capital
04/08/20 Needham
Smart Global price target lowered to $35 from $45 at Needham
SGH Smart Global
$28.20 /

+0.52 (+1.88%)

SGH Smart Global
$28.20 /

+0.52 (+1.88%)

SGH Smart Global
$28.20 /

+0.52 (+1.88%)

Recommendations
AMC Entertainment price target raised to $4 from $3 at Imperial Capital » 05:09
06/05/20
06/05
05:09
06/05/20
05:09
AMC

AMC Entertainment

$5.39 /

-0.015 (-0.28%)

Imperial Capital analyst…

Imperial Capital analyst David Miller raised the firm's price target on AMC Entertainment to $4 from $3 and keeps an In-Line rating on the shares ahead of the company's Q1 results.

ShowHide Related Items >><<
AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

06/03/20 Barrington
Operating environment creates going concern uncertainty for AMC, says Barrington
05/27/20
Fly Intel: Top five analyst upgrades
05/27/20 MKM Partners
AMC Entertainment upgraded to Neutral from Sell at MKM Partners
05/27/20 MKM Partners
AMC Entertainment upgraded to Neutral from Sell at MKM Partners
AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

Upgrade
Novavax upgraded to Neutral from Underweight at JPMorgan » 04:42
06/05/20
06/05
04:42
06/05/20
04:42
NVAX

Novavax

$44.68 /

+0.42 (+0.95%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph upgraded Novavax to Neutral from Underweight with a $46 price target.

ShowHide Related Items >><<
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/03/20 B. Riley FBR
Novavax selloff on 'Warp Speed' report unwarranted, says B. Riley FBR
05/26/20 B. Riley FBR
Novavax has become a leading COVID vaccine candidate, says B. Riley FBR
05/18/20 B. Riley FBR
Novavax price target raised to $53 from $43 at B. Riley FBR
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

Thursday
Hot Stocks
Novavax awarded $60M contract from U.S. Defense Dept for COVID-19 vaccine » 20:25
06/04/20
06/04
20:25
06/04/20
20:25
NVAX

Novavax

$44.68 /

+0.42 (+0.95%)

Novavax announced that…

Novavax announced that the company has been awarded a contract by the U.S. Department of Defense for the manufacturing of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. "JPEO-CRBND-EB through funding provided by the Defense Health Program, has agreed to fund up to $60M to support Novavax in its production of several components of the vaccine that will be manufactured in the U.S. The agreement includes a 2020 delivery of 10M doses of NVX-CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization, if approved by the U.S. FDA", the company states in its press release.

ShowHide Related Items >><<
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/03/20 B. Riley FBR
Novavax selloff on 'Warp Speed' report unwarranted, says B. Riley FBR
05/26/20 B. Riley FBR
Novavax has become a leading COVID vaccine candidate, says B. Riley FBR
05/18/20 B. Riley FBR
Novavax price target raised to $53 from $43 at B. Riley FBR
NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

NVAX Novavax
$44.68 /

+0.42 (+0.95%)

Periodicals
More than half of American retailers skipped on rent in April, May, BI says » 17:17
06/04/20
06/04
17:17
06/04/20
17:17
BBBY

Bed Bath & Beyond

$8.75 /

+0.66 (+8.16%)

, GPS

Gap

$12.14 /

+0.195 (+1.63%)

, AMC

AMC Entertainment

$5.39 /

-0.015 (-0.28%)

According to Business…

According to Business Insider, citing an earlier story from the Washington Post's Heather Long, "Bed Bath & Beyond (BBBY), Famous Footwear, H&M, and the Gap (GPS), AMC (AMC) and Regal movie theaters, and 24 Hour Fitness gyms have all missed payments, jeopardizing the stability of their property management companies and municipal governments that rely on property taxes." Reference Link

ShowHide Related Items >><<
GPS Gap
$12.14 /

+0.195 (+1.63%)

BBBY Bed Bath & Beyond
$8.75 /

+0.66 (+8.16%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

BBBY Bed Bath & Beyond
$8.75 /

+0.66 (+8.16%)

05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
03/23/20 Odeon Capital
Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
GPS Gap
$12.14 /

+0.195 (+1.63%)

06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 JPMorgan
Gap upgraded to Neutral from Underweight on valuation at JPMorgan
06/01/20 JPMorgan
Gap upgraded to Neutral from Underweight at JPMorgan
04/27/20 Barclays
Gap price target lowered to $5 from $10 at Barclays
AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

06/03/20 Barrington
Operating environment creates going concern uncertainty for AMC, says Barrington
05/27/20
Fly Intel: Top five analyst upgrades
05/27/20 MKM Partners
AMC Entertainment upgraded to Neutral from Sell at MKM Partners
05/27/20 MKM Partners
AMC Entertainment upgraded to Neutral from Sell at MKM Partners
GPS Gap
$12.14 /

+0.195 (+1.63%)

BBBY Bed Bath & Beyond
$8.75 /

+0.66 (+8.16%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

BBBY Bed Bath & Beyond
$8.75 /

+0.66 (+8.16%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

BBBY Bed Bath & Beyond
$8.75 /

+0.66 (+8.16%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

BBBY Bed Bath & Beyond
$8.75 /

+0.66 (+8.16%)

AMC AMC Entertainment
$5.39 /

-0.015 (-0.28%)

BBBY Bed Bath & Beyond
$8.75 /

+0.66 (+8.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.